Zydus Lifesciences Limited — Bevacizumab Exporter Profile
Indian Pharmaceutical Exporter · #5 for Bevacizumab · $1.1M export value · DGFT Verified
Zydus Lifesciences Limited is the #5 Indian exporter of Bevacizumab with $1.1M in export value and 21 verified shipments. Zydus Lifesciences Limited holds a 2.2% market share in Bevacizumab exports across 4 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Bevacizumab Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Bevacizumab?
Zydus Lifesciences Limited exports Bevacizumab to 4 countries. The largest destination is MEXICO accounting for 52.4% of Zydus Lifesciences Limited's Bevacizumab shipments, followed by BOLIVIA (29.2%) and NEPAL (10.2%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Bevacizumab from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ZYDUS PHARMACEUTICALS M?XICO S.A. D | MEXICO | $150.0K | 3 |
| FARMEDICAL S.R.L. | BOLIVIA | $83.5K | 3 |
| D. K. M. PHARMACEUTICALS PVT. LTD. | NEPAL | $19.8K | 9 |
| RIPPLE PHARMACEUTICALS LTD | KENYA | $14.1K | 1 |
| RIPPLE PHARMACEUTICALS LIMITED | KENYA | $9.6K | 1 |
| D K M PHARMACEUTICALS PVT LTD | NEPAL | $9.4K | 4 |
Zydus Lifesciences Limited supplies Bevacizumab to 6 buyers globally. The largest buyer is ZYDUS PHARMACEUTICALS M?XICO S.A. D (MEXICO), followed by FARMEDICAL S.R.L. (BOLIVIA) and D. K. M. PHARMACEUTICALS PVT. LTD. (NEPAL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Bevacizumab Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $15.2M worth of Bevacizumab through 1,408 shipments from 196 suppliers to 100 countries, serving 346 buyers globally. Zydus Lifesciences Limited contributes $1.1M to this total, accounting for 2.2% of India's Bevacizumab exports. Zydus Lifesciences Limited ships Bevacizumab to 4 countries through 6 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Bevacizumab Exports?
Zydus Lifesciences Limited's average Bevacizumab shipment value is $50.0K per consignment, based on 21 shipments totaling $1.1M. The largest destination is MEXICO (52.4% of Zydus Lifesciences Limited's Bevacizumab exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Bevacizumab Exporters?
Zydus Lifesciences Limited ranks #5 among 196 Indian Bevacizumab exporters with a 2.2% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($6.5M), BIOCON BIOLOGICS INDIA LIMITED ($2.3M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($2.1M). Zydus Lifesciences Limited processed 21 shipments to 4 destination countries.
What Bevacizumab Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| Bhava(Bevacizumab Inj400mg/16mL)VialSLMX(BEVACIZUMAB) | $150.0K | 3 |
| BRYXTA 100MG INJECTION VIAL BOLIVIA (BEVACIZUMAB)(1X1 VIAL)VLS | $49.2K | 1 |
| BRYXTA 100MG INJECTION VIAL BOLIVIA (BEVACIZUMAB)(1X1 VIAL) | $24.6K | 1 |
| BRYXTA 400MG (BEVACIZUMAB 400MG/ 16ML) ( | $14.1K | 1 |
| BEVACIZUMAB 100 MG / 4ML (BRYXTA 100MG INJECTION VIAL BOLIVIA) 1 X 1 VIAL | $9.7K | 1 |
| BRYXTA 400MG INJECTION VIAL KENYA BEVACIZUMAB 1 X 1 VIAL AS PER INV | $9.6K | 1 |
| BRYXTA INJECTION 400MG/16ML VIAL (BEVACIZUMAB 400MG) (BATCH NO. B400469 MFG. DT.08/2024 & EXP. DT. 07/2027) | $7.5K | 2 |
| BRYXTA INJECTION 400MG 16ML VIAL BEVACIZUMAB 400MG BATCH NO V500069 MFG DT 02 2025 EXP DT 01 2028 | $6.4K | 1 |
| BRYXTA INJECTION 400MG/16ML VIAL (BEVACIZUMAB 400MG) BATCH NO. B400228 MFG. DT.03/2024 & EXP. DT. 02/2027 | $5.3K | 1 |
| BRYXTA INJECTION 100MG/4ML VIAL (BEVACIZUMAB 100MG) (BATCH NO. B400502 MFG. DT.08/2024 & EXP. DT. 07/2027) | $2.1K | 2 |
Zydus Lifesciences Limited exports 16 distinct Bevacizumab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is Bhava(Bevacizumab Inj400mg/16mL)VialSLMX(BEVACIZUMAB) with 3 shipments worth $150.0K.
Regulatory Requirements: Exporting Bevacizumab to Key Markets
What Zydus Lifesciences Limited must comply with to export Bevacizumab to its top destination countries
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Zydus Lifesciences Limited Compare to Nearest Bevacizumab Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | BIOCON BIOLOGICS INDIA LIMITED | $2.3M | 46 | 12 | $50.0K |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $2.1M | 73 | 12 | $29.1K |
| 5 | ZYDUS LIFESCIENCES LIMITED ★ | $1.1M | 21 | 4 | $50.0K |
| 3 | DR REDDY S LABORATORIES LTD | $700.0K | 14 | 1 | $50.0K |
| 7 | MYLAN PHARMACEUTICALS PRIVATE LIMITED | $650.0K | 13 | 5 | $50.0K |
Zydus Lifesciences Limited ranks #5 among 196 Indian Bevacizumab exporters. Average shipment value of $50.0K compared to the market average of $77.5K. The closest competitors by value are BIOCON BIOLOGICS INDIA LIMITED and RELIANCE LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Bevacizumab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 345 | 24.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 327 | 23.2% |
| HYDERABAD ACC (INHYD4) | 132 | 9.4% |
| Bombay Air | 89 | 6.3% |
| DELHI AIR CARGO ACC (INDEL4) | 48 | 3.4% |
| DELHI AIR | 47 | 3.3% |
| HYDERABAD AIR | 36 | 2.6% |
| AHEMDABAD AIR | 32 | 2.3% |
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Bevacizumab Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Bevacizumab, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Bevacizumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Bevacizumab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 21 individual customs records matching Zydus Lifesciences Limited exporting Bevacizumab, covering 16 formulations to 4 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 100+ countries, 346+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Bevacizumab Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Bevacizumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Bevacizumab Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Bevacizumab. For current shipment-level data, contact TransData Nexus.